Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

12 Oct 2018

Abstract excerpt

Olaparib (Lynparza™) is a PARP inhibitor approved for advanced BRCA -mutated ( BRCA m) ovarian cancer. PARP inhibitors may benefit patients whose tumours are dysfunctional in DNA repair mechanisms unrelated to BRCA1/2 . We report exploratory analyses, including the long-term outcome of candidate biomarkers of sensitivity to olaparib in BRCA wild-type ( BRCA wt) tumours. Tumour samples from an olaparib maintenance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30353044
DOI: 10.1038/s41416-018-0274-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genesPMID 30353044Read ↗

Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian Cancer.Semantic proximity Read ↗

The Role of Tumor Biomarkers in Tailoring the Approach to Advanced Ovarian Cancer.Semantic proximity Read ↗

Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.Semantic proximity Read ↗

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian CancerSemantic proximity Read ↗

Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian CancerSemantic proximity Read ↗

Ovarian carcinoma patients with a tumor<i>BRCA</i>-like genomic copy number aberration profile benefit from maintenance olaparib/bevacizumab therapy in the PAOLA-1 randomized controlled trialSemantic proximity Read ↗

Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer.Semantic proximity Read ↗

Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib.Semantic proximity Read ↗

Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinomaSemantic proximity Read ↗

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.Semantic proximity Read ↗

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP InhibitorsSemantic proximity Read ↗

Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.